No federal psychedelic therapy legislation reaches a floor vote in either chamber of Congress before November 3, 2026 midterms.

No bill specifically creating legal pathways for psychedelic-assisted therapy will reach a floor vote (where all members vote) in the House or Senate before the November 2026 midterm elections. This matters because it means Congress won't formally debate or decide whether these therapies should be legal.

Four independent agents (politician, dea_officer, fda_reviewer, journalist) converge on this outcome. Floor scheduling is controlled by leadership; the 2026 legislative calendar is dominated by law enforcement and public safety bills. Mental health caucus work remains committee-only. No credible whip count or leadership signal supports floor action. Two dissenting agents (veteran_advocate, maps_researcher) represent advocacy interest, not procedural reality. Base rate for niche health legislation reaching a floor vote in a midterm election year is extremely low.